Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MedWellAi, Inc Joins Trump Mobile In Engaging BrighterMD To Develop Ai-Inhanced Healthcare Telemedicine Platform, Focused On $24.46 Billion Corporate Wellness Market - MedWellAI ( OTC:MWAI )
CLEARWATER, Fla., Aug. 18, 2025 /PRNewswire/ -- MedWell Ai, Inc, ( "Company" ) MWAI is pleased to confirm the collaboration and execution of Software Development Agreement with BrighterMD, to develop and launch Company's latest initiative: TeleMD.Ai - Nationwide B2B and B2C Healthcare and ...
Here's Why Quest Diagnostics ( DGX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Does the Market Think About Quest Diagnostics? - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has risen 3.64% since its last report. The company recently reported that it has 4.74 million shares sold short, which is 4.84% of all regular shares that are available for trading.
OraSure Appoints Anne Messing as Chief Commercial Officer
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) ( NASDAQ: OSUR ) , a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
OraSure Appoints Anne Messing as Chief Commercial Officer - OraSure Technologies ( NASDAQ:OSUR )
BETHLEHEM, Pa., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- OraSure Technologies, Inc. ( "OTI" ) OSUR, a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer.
Healthcare Analytical Testing Services Market is expected to generate a revenue of USD 9.56 Billion by 2031, Globally, at 11.20% CAGR: Verified Market Research®
Lewes, Delaware, July 31, 2025 ( GLOBE NEWSWIRE ) -- The Global Healthcare Analytical Testing Services Market Size is projected to grow at a CAGR of 11.20% from 2024 to 2031, according to a new report published by Verified Market Research®.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Quest Diagnostics ( DGX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
C3.ai Expands Beyond Oil: Is Diversification Paying Off?
AI's 48% surge in non-oil revenue and major wins in 19 industries show its diversification strategy gaining real ground.
Quest Diagnostics Raises 2025 Guidance
Diagnostic testing and information services provider Quest Diagnostics ( NYSE:DGX ) reported fiscal 2025 second-quarter results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue hit $2.76 billion and adjusted earnings per share ( EPS ) came in at $2.62.
Looking Into Quest Diagnostics's Recent Short Interest - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics's DGX short percent of float has risen 36.83% since its last report. The company recently reported that it has 4.98 million shares sold short, which is 5.09% of all regular shares that are available for trading.
Quest Diagnostics Boosts Its 2025 Outlook
Quest Diagnostics ( NYSE:DGX ) reported its second-quarter 2025 results on July 22, achieving consolidated revenue of $2.76 billion ( up 15.2% year over year ) , organic revenue growth of 5.2%, while adjusted EPS rose 11.5% year over year to $2.62.
Quest Diagnostics Q2 Earnings - Quest Diagnostics ( NYSE:DGX )
Q1 revenue rose 15.2% Y/Y to $2.76B, beating the $2.73B estimate; EPS of $2.62 topped the $2.58 consensus. Quest raised 2025 revenue forecast to $10.80 billion-$10.92 billion and EPS to $9.63-$9.83, above prior guidance and consensus.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
Quest ( DGX ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, July 22, 2025 at 8:30 a.m. ETChairman, Chief Executive Officer, and President - Jim DavisContinue reading ...
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Quest Diagnostics ( DGX ) Beats Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) delivered earnings and revenue surprises of +1.95% and +1.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 493.73% on an annualized basis producing an average annual return of 508.21%. Currently, Quest Diagnostics has a market capitalization of $18.63 billion.
Should You Buy Quest Diagnostics Ahead of Earnings?
DGX is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Will Quest Diagnostics ( DGX ) Beat Estimates Again in Its Next Earnings Report?
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics ( DGX ) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Paysafe and Champion Homes have been highlighted as Zacks Bull and Bear of the Day
PSFE earns Bull of the Day with deep value and rising earnings, while SKY's short surge and weak outlook land it as Bear of the Day.
Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors
Berberian brings significant technology leadership and cybersecurity expertise Berberian brings significant technology leadership and cybersecurity expertise ...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 304.48% on an annualized basis producing an average annual return of 318.82%. Currently, Quest Diagnostics has a market capitalization of $19.42 billion.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
Zacks Industry Outlook Highlights Quest Diagnostics, Encompass Health, DaVita and The Pennant
DGX, EHC, DVA, and PNTG are riding the outpatient healthcare shift as tech, AI, and aging demand reshape the care landscape.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
Quest Diagnostics ( DGX ) Upgraded to Buy: Here's What You Should Know
Quest Diagnostics (DGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Guardant Health ( NASDAQ:GH ) , Quest Diagnostics ( NYSE:DGX ) , Exact Sciences ( NASDAQ:EXAS ) , Labcorp Hldgs ( NYSE:LH )
BofA raised Tempus AI's price forecast to $70 but maintained a Neutral rating due to valuation concerns. Guardant Health, Exact Sciences, and LabCorp received Buy ratings for AI-aligned precision medicine strategies. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 299.46% on an annualized basis producing an average annual return of 313.78%. Currently, Quest Diagnostics has a market capitalization of $20.33 billion.
Take the Zacks Approach to Beat the Markets: Mirion Technologies, Avino Silver & Gold Mines, Quanta Services in Focus
MIR, ASM and PWR outperform the S&P 500 after Zacks upgrades, spotlighting key stock picks in a volatile market.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
Quest Diagnostics to Develop Multi-cancer Stratification ( MCaST ) Blood Test Based on MD Anderson Technology - Quest Diagnostics ( NYSE:DGX )
SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics DGX, a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center ( MD Anderson ) designed to improve the assessment of elevated risk of cancer in ...
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 276.89% on an annualized basis producing an average annual return of 290.74%. Currently, Quest Diagnostics has a market capitalization of $19.32 billion.
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
The women's health market is booming, with Hologic and Quest Diagnostics leading the charge. But which one stands out more for investors today?
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 305.46% on an annualized basis producing an average annual return of 320.73%. Currently, Quest Diagnostics has a market capitalization of $19.47 billion.
Should You Continue to Retain DGX Stock in Your Portfolio?
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Quest Diagnostics ( NYSE:DGX ) , Castle Biosciences ( NASDAQ:CSTL )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut ON Semiconductor Corporation ON price target from $57 to $50.
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics DGX has outperformed the market over the past 5 years by 290.7% on an annualized basis producing an average annual return of 304.55%. Currently, Quest Diagnostics has a market capitalization of $19.69 billion.
C3.ai Stock Below 50- & 200-Day SMAs: Turnaround or More Pain?
C3.ai stock is down, but the growth story is heating up. With big tech partners and growing revenues, is C3.ai gearing up for a major AI comeback?
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Quest Diagnostics ( NYSE:DGX )
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday. Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share.
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence - Quest Diagnostics ( NYSE:DGX )
Q1 revenue rose 12.1% to $2.65 billion, beating estimates; adjusted EPS climbed 8.3% to $2.21. Adjusted operating income grew 16.3% to $406 million; margin expanded to 15.3% from 14.8%. China's new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for ...
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
DGX delivers solid top-line growth in the first quarter of 2025.
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday - Akso Health ( NASDAQ:AHG ) , Bitdeer Technologies ( NASDAQ:BTDR )
U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday. Shares of Quest Diagnostics Incorporated DGX rose sharply during Tuesday's session following better-than-expected first-quarter earnings.
